Medicare AdvantagePrior AuthMedium impact
Dopamine Agonists (Revised)
Humana·Neurology, Geriatrics, Internal Medicine·Medicare Advantage
Effective date
Jan 1, 2023
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage updated its Dopamine Agonists step therapy policy (revised 11/26/2025). The policy requires members to have tried or be unable to use immediate-release pramipexole AND immediate-release ropinirole before approval for extended-release formulations (Mirapex ER, pramipexole ER, ropinirole ER) or Neupro patches. This is a step therapy requirement that mandates prior authorization for these medications.
Action Required
Immediately: Prior to submitting pharmacy claims for Mirapex ER, pramipexole ER, ropinirole ER, or Neupro (rotigotine) patches to Humana Medicare Advantage plans, the billing/pharmacy team must verify that the member has documentation of prior trial or contraindication to BOTH immediate-release pramipexole tablets AND immediate-release ropinirole tablets. Update pharmacy prior authorization workflows and claim submission procedures to require this step therapy documentation. Without evidence of meeting Criterion #1 (prior trial or inability to use both immediate-release agents), claims will be denied. Coordinate with prescribing providers to ensure they document treatment history with immediate-release dopamine agonists on all Mirapex ER, pramipexole ER, ropinirole ER, and Neupro requests submitted to Humana MA plans.